ScreenerHero
DBVDBV Technologies S.A.
EPA · FR · Healthcare · Biotechnology · dbv-technologies.com
2.484EUR+0.57%Mkt Cap: 853.20M $P/E: —

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherap…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap853.20M $
Enterprise Value620.45M $
Revenue (TTM)5.47M $
Gross Profit5.47M $
Net Income (TTM)-159.72M $
Revenue/Share0.0185 USD
Last Price2.484 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees170
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.08
PEG—
EV/EBITDA-3.27
EV/Revenue113.35
P/S155.62
P/B5.37
EPS (TTM)-0.60
EPS (Forward)-0.15
52W Range
1.44834% of range4.500
52W High4.500 EUR
52W Low1.448 EUR
Profitability
Gross Margin100.00%
Oper. Margin-7228.57%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-87.07%
ROA-62.87%
Growth
Revenue Growth-53.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-131.72M $
CapEx (TTM)584.78K $
FCF Margin-2081.96%
FCF Yield-13.36%
Net Debt-181.74M $
Net Debt/EBITDA0.96
Balance Sheet
Debt/Equity0.05
Current Ratio3.72
Quick Ratio3.54
Book Value/Sh0.4643 EUR
Cash/Share0.5910 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.637 EUR
Upside (mean)+46.4%
Target Range1.000 EUR – 5.500 EUR
€1.000+46.4% to mean€5.500
# Analysts3
Ownership
Shares Out.314.23M
Float174.70M
Insiders0.13%
Institutions53.55%
Technical
SMA 502.653 (-6.4%)
SMA 2003.161 (-21.4%)
Beta-0.24
S&P 52W Chg18.16%
Avg Vol (30d)890.77K
Avg Vol (10d)1.16M
Technical Indicators
RSI (14)47.3
MACD-0.0388
MACD Signal-0.0707
MACD Hist.+0.0319
BB Upper2.566 EUR
BB Middle2.422 EUR
BB Lower2.279 EUR
BB Width11.83%
ATR (14)0.1217 EUR
Vol Ratio (20d)1.41x